0001209191-15-009188.txt : 20150203 0001209191-15-009188.hdr.sgml : 20150203 20150203204711 ACCESSION NUMBER: 0001209191-15-009188 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150130 FILED AS OF DATE: 20150203 DATE AS OF CHANGE: 20150203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MYLAN INC. CENTRAL INDEX KEY: 0000069499 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 251211621 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1000 MYLAN BOULEVARD CITY: CANONSBURG STATE: PA ZIP: 15317 BUSINESS PHONE: 724-514-1800 MAIL ADDRESS: STREET 1: 1000 MYLAN BOULEVARD CITY: CANONSBURG STATE: PA ZIP: 15317 FORMER COMPANY: FORMER CONFORMED NAME: MYLAN LABORATORIES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FRM CORP DATE OF NAME CHANGE: 19711003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PARRISH MARK W CENTRAL INDEX KEY: 0001236452 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09114 FILM NUMBER: 15573250 MAIL ADDRESS: STREET 1: C/O CARDINAL HEALTH INC STREET 2: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43235 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-01-30 0 0000069499 MYLAN INC. MYL 0001236452 PARRISH MARK W 1000 MYLAN BLVD CANONSBURG PA 15317 1 0 0 0 Common Stock 2015-01-30 4 M 0 12147 14.27 A 41807 D Common Stock 2015-01-30 4 M 0 2709 20.52 A 44516 D Common Stock 2015-01-30 4 S 0 14856 53.7283 D 29660 D Common Stock 2015-02-02 4 M 0 8917 20.52 A 38577 D Common Stock 2015-02-02 4 M 0 10864 23.90 A 49441 D Common Stock 2015-02-02 4 M 0 3438 21.00 A 52879 D Common Stock 2015-02-02 4 S 0 23219 52.8739 D 29660 D Common Stock 2015-02-03 4 M 0 9720 21.00 A 39380 D Common Stock 2015-02-03 4 M 0 6623 31.63 A 46003 D Common Stock 2015-02-03 4 S 0 16343 53.0135 D 29660 D Non-Employee Director Stock Option - Right to Buy 14.27 2015-01-30 4 M 0 12147 0.00 D 2019-09-01 Common Stock 12147 0 D Non-Employee Director Stock Option - Right to Buy 20.52 2015-01-30 4 M 0 2709 0.00 D 2020-05-14 Common Stock 2709 8917 D Non-Employee Director Stock Option - Right to Buy 20.52 2015-02-02 4 M 0 8917 0.00 D 2020-05-14 Common Stock 8917 0 D Non-Employee Director Stock Option - Right to Buy 23.90 2015-02-02 4 M 0 10864 0.00 D 2021-05-06 Common Stock 10864 0 D Non-Employee Director Stock Option - Right to Buy 21.00 2015-02-02 4 M 0 3438 0.00 D 2022-05-04 Common Stock 3438 9720 D Non-Employee Director Stock Option - Right to Buy 21.00 2015-02-03 4 M 0 9720 0.00 D 2022-05-04 Common Stock 9720 0 D Non-Employee Director Stock Option - Right to Buy 31.63 2015-02-03 4 M 0 6623 0.00 D 2023-05-28 Common Stock 6623 0 D Represents acquisition of Mylan common stock upon exercise of stock options granted on September 1, 2009. Represents acquisition of Mylan common stock upon exercise of stock options granted on May 14, 2010. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on January 30, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 403,595 shares in transactions ranging from $53.01 to $54.00 with a weighted average price of $53.5684 as well as 205,341 shares in transactions ranging from $54.005 to $54.25 with a weighted average price of $54.0425. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person. Represents acquisition of Mylan common stock upon exercise of stock options granted on May 6, 2011. Represents acquisition of Mylan common stock upon exercise of stock options granted on May 4, 2012. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 2, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 937,763 shares in transactions ranging from $52.23 to $53.22 with a weighted average price of $52.8646 as well as 13,957 shares in transactions ranging from $53.23 to $53.745 with a weighted average price of $53.5027. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person. Represents acquisition of Mylan common stock upon exercise of stock options granted on May 28, 2013. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 3, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 520,475 shares in transactions ranging from $52.50 to $53.25 with a weighted average price of $52.8739 as well as 149,400 shares at $53.50 and 1 share at $54.50. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person. This option exercise and the related sale of the underlying common stock were executed pursuant to a 10b5-1 trading plan dated November 9, 2014. These options vested in full on September 1, 2010. These options vested in full on May 14, 2011. These options vested in full on May 6, 2012. These options vested in full on May 4, 2013. These options vested in full on May 28, 2014. As disclosed in the proxy statement filed by Mylan Inc. ("Mylan") on December 24, 2014 and the Form 8-K filed by Mylan on November 5, 2014, the filing person has exercised the stock options shown on this Form 4 to mitigate the effects of the excise tax under Section 4985 of the Internal Revenue Code of 1986, as amended, in connection with the proposed acquisition (the "Transaction") by a new public company organized in the Netherlands of both Mylan and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business and has sold the shares reported on this Form 4 to mitigate the tax and other costs imposed as a result of such exercises and the Transaction. /s/ Bradley L. Wideman, by power of attorney 2015-02-03